文献速递乳腺外科围术期管理与 ERAS

自体脂肪移植联合扩张装置与假体乳房重建对乳腺癌患者生活质量的影响:一项随机临床试验

Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2023-01-01

BREAST试验在荷兰7家医院纳入193例乳房切除术后寻求重建的乳腺癌患者,随机分配至自体脂肪移植(AFT)联合扩张装置组或两阶段假体乳房重建(IBR)组,随访12个月。AFT组BREAST-Q全部5个维度评分均较高,其中3个维度显著更高,且随时间推移生活质量改善更有利于AFT;两组肿瘤学严重不良事件无差异。

要点

  • AFT联合扩张装置在乳房满意度、胸部生理健康和结局满意度上显著优于IBR。
  • AFT组平均重建乳房体积为300.3 mL,小于IBR组的384.1 mL。
  • 两组肿瘤学严重不良事件无差异,AFT未显示不安全信号。

核心结论

  • 对于接受乳房切除术的乳腺癌患者,AFT联合扩张装置相比IBR可获得更高的生活质量和随时间改善的生活质量评分。
  • 未发现AFT不安全的证据,为乳腺癌患者提供了第三种创伤更小的重建选择。

研究设计与样本

  • BREAST试验为随机临床试验,2015年11月2日至2021年10月31日在荷兰7家医院开展,随访12个月。
  • 共纳入193例18岁以上接受乳房切除术并寻求乳房重建的女性患者,按1:1随机分配,AFT组91例、IBR组80例接受分配干预。
  • 接受乳房切除术后放疗的患者被排除,纳入前由参与研究的整形外科医生根据放疗史和体型筛查资格。
  • 主要结局为末次手术后12个月的生活质量,采用BREAST-Q问卷(0至100分,分数越高满意度或生活质量越好)测量,统计分析按方案进行。

主要发现

  • AFT组和IBR组分别有64例和68例完成随访;IBR组18例退出主要因不愿使用假体,AFT组6例因治疗负担提前终止。
  • 线性混合效应回归分析显示生活质量随时间的变化依赖于治疗分组,结果有利于AFT。
  • 平均(SD)重建乳房体积AFT组为300.3(111.4)mL,IBR组为384.1(86.6)mL。
  • 两组肿瘤学严重不良事件无差异。

关键数值与推荐

  • 主要结局采用BREAST-Q问卷评分,0至100分,分数越高表示满意度或生活质量越好。
  • 平均重建乳房体积:AFT组300.3(111.4)mL,IBR组384.1(86.6)mL。

临床怎么用

  • 对于乳房切除术后寻求重建且未接受术后放疗的乳腺癌患者,可考虑AFT联合扩张装置作为创伤更小的重建选项。
  • 选择AFT时需告知患者重建乳房体积可能小于假体重建,但生活质量和满意度可能更高。
  • AFT治疗过程可能带来较重或较疲劳的负担,需在围术期管理中充分沟通和 support。

局限性

  • AFT组6例因治疗负担提前终止、IBR组18例因不愿使用假体退出,可能影响按方案分析结果的解释。
  • 研究在荷兰7家医院开展,随访12个月,长期安全性和效果未报告。
  • 排除接受术后放疗的患者,结论不适用于该人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is a need for a new, less invasive breast reconstruction option for patients who undergo mastectomy in their breast cancer treatment. OBJECTIVE: To investigate quality of life (QoL) among patients undergoing a new breast reconstruction technique, autologous fat transfer (AFT), compared with that among patients undergoing implant-based reconstruction (IBR). DESIGN, SETTING, AND PARTICIPANTS: The BREAST trial was a randomized clinical trial conducted between November 2, 2015, and October 31, 2021, performed in 7 hospitals across the Netherlands. Follow-up was 12 months. Referrals could be obtained from general practitioners and all departments from participating or nonparticipating hospitals. The patients with breast cancer who had undergone mastectomy and were seeking breast reconstruction were screened for eligibility (radiotherapy history and physique) by participating plastic surgeons. Patients receiving postmastectomy radiotherapy were excluded. INTERVENTIONS: Breast reconstruction with AFT plus expansion or 2-phased IBR. Randomization was done in a 1:1 ratio. MAIN OUTCOMES AND MEASURES: The statistical analysis was performed per protocol. The predefined primary outcome was QoL at 12 months after final surgery. This was measured by the BREAST-Q questionnaire, a validated breast reconstruction surgery questionnaire. Questions on the BREAST-Q questionnaire are scored from 0 to 100, with a higher score indicating greater satisfaction or better QoL (depending on the scale). Secondary outcomes were breast volume and the safety and efficacy of the techniques. RESULTS: A total of 193 female patients (mean [SD] age, 49.2 [10.6] years) 18 years or older who desired breast reconstruction were included, of whom 91 patients in the AFT group (mean [SD] age, 49.3 [10.3] years) and 80 in the IBR group (mean age, 49.1 [11.0] years) received the allocated intervention. In total, 64 women in the AFT group and 68 women in the IBR group completed follow-up. In the IBR group, 18 patients dropped out mainly due to their aversion to implant use while in the AFT group 6 patients ended their treatment prematurely because of the burden (that is, the treatment being too heavy or tiring). The BREAST-Q scores were higher in the AFT group in all 5 domains and significantly higher in 3: satisfaction with breasts (difference, 9.9; P = .002), physical well-being: chest (difference; 7.6; P = .007), and satisfaction with outcome (difference, 7.6; P = .04). Linear mixed-effects regression analysis showed that QoL change over time was dependent on the treatment group in favor of AFT. The mean (SD) breast volume achieved differed between the groups (AFT: 300.3 [111.4] mL; IBR: 384.1 [86.6] mL). No differences in oncological serious adverse events were found. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found higher QoL and an increase in QoL scores over time in the AFT group compared with the IBR group. No evidence was found that AFT was unsafe. This is encouraging news since it provides a third, less invasive reconstruction option for patients with breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02339779.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Piatkowski AA, Wederfoort JLM, Hommes JE, et al. Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial. JAMA Surg. 2023. PMID: 36857058. doi:10.1001/jamasurg.2022.7625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。